{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:08:57Z","timestamp":1788912537690,"version":"build-2803163510"},"reference-count":301,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009367","name":"Mansoura University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009367","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment of hematological malignancies, yet its broader application to solid tumors, chronic viral infections, and autoimmune diseases remains constrained by antigen heterogeneity, immunosuppressive tissue microenvironments, T-cell exhaustion, limited persistence, and treatment-associated toxicities. These challenges have shifted the field from optimizing individual receptor constructs toward engineering CAR-T cells as programmable immune systems capable of adapting to diverse disease contexts. This review synthesizes recent advances in molecular engineering strategies that enhance CAR-T cell function beyond conventional receptor design. We discuss how receptor engineering, genome editing, transcriptional and epigenetic regulation, metabolic reprogramming, synthetic gene circuits, and safety-control platforms collectively reshape CAR-T cell fate, persistence, and therapeutic efficacy. Rather than functioning independently, these engineering strategies are increasingly integrated to generate context-specific cellular therapies capable of adapting to diverse disease environments, including cancer, autoimmune diseases, and chronic viral infections. We also highlight the potential for translation into clinical practice or clinical translation and discuss the major challenges associated with clinical implementation. Next-generation CAR-T therapies will increasingly integrate molecular engineering strategies or will rely on molecular engineering strategies to integrate antigen recognition, cellular fitness, immune regulation, and longevity rather than simply maximizing cytotoxic activity. Recent advances in programmable cellular engineering coupled with rigorous clinical evaluation as well as scalable manufacturing technologies or scalable manufacturing platforms in the treatment of other diseases beyond oncology will facilitate the development of safer, more durable, and broadly applicable cellular therapies.<\/jats:p>","DOI":"10.1186\/s13287-026-05266-0","type":"journal-article","created":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T07:04:11Z","timestamp":1788678251000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recent advances in molecular mechanisms to improve the efficacy of CAR-T cell therapy for viral diseases, cancer, and autoimmune diseases"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0069-4212","authenticated-orcid":false,"given":"Hany E.","family":"Marei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Pozzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Caratelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Cenciarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,6]]},"reference":[{"key":"5266_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379:64\u201373.","journal-title":"N Engl J Med"},{"key":"5266_CR2","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/s41417-025-00931-7","volume":"32","author":"Z Tu","year":"2025","unstructured":"Tu Z, Chen Y, Zhang Z, Meng W, Li L. Barriers and solutions for CAR-T therapy in solid tumors. Cancer Gene Ther. 2025;32:923\u201334.","journal-title":"Cancer Gene Ther"},{"key":"5266_CR3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat reviews Clin Oncol. 2020;17:147\u201367.","journal-title":"Nat reviews Clin Oncol"},{"key":"5266_CR4","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone M. C. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361\u20135.","journal-title":"Science"},{"key":"5266_CR5","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15:486\u201399.","journal-title":"Nat Rev Immunol"},{"key":"5266_CR6","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","volume":"19","author":"CU Blank","year":"2019","unstructured":"Blank CU, et al. Defining \u2018T cell exhaustion\u2019. Nat Rev Immunol. 2019;19:665\u201374.","journal-title":"Nat Rev Immunol"},{"key":"5266_CR7","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nature22395","volume":"545","author":"M Sadelain","year":"2017","unstructured":"Sadelain M, Rivi\u00e8re I, Riddell S. Therapeutic T cell engineering. Nature. 2017;545:423\u201331.","journal-title":"Nature"},{"key":"5266_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem J, et al. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature. 2017;543:113\u20137.","journal-title":"Nature"},{"key":"5266_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood cancer J. 2021;11:69.","journal-title":"Blood cancer J"},{"key":"5266_CR10","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41577-024-01093-7","volume":"25","author":"S Minguet","year":"2025","unstructured":"Minguet S, Maus MV, Schamel WW. From TCR fundamental research to innovative chimeric antigen receptor design. Nat Rev Immunol. 2025;25:212\u201324.","journal-title":"Nat Rev Immunol"},{"key":"5266_CR11","doi-asserted-by":"crossref","unstructured":"Li YR, Zhu Y, Halladay T, Yang L. In vivo CAR engineering for immunotherapy. Nat Rev Immunol. 2025;25(10):725\u201344.","DOI":"10.1038\/s41577-025-01174-1"},{"key":"5266_CR12","doi-asserted-by":"publisher","first-page":"1407992","DOI":"10.3389\/fimmu.2024.1407992","volume":"15","author":"AM Alviano","year":"2024","unstructured":"Alviano AM, et al. Fully equipped CARs to address tumor heterogeneity, enhance safety, and improve the functionality of cellular immunotherapies. Front Immunol. 2024;15:1407992.","journal-title":"Front Immunol"},{"key":"5266_CR13","doi-asserted-by":"publisher","first-page":"e20230903","DOI":"10.1084\/jem.20230903","volume":"221","author":"M Ayala Ceja","year":"2024","unstructured":"Ayala Ceja M, Khericha M, Harris CM, Puig-Saus C, Chen Y. Y. CAR-T cell manufacturing: Major process parameters and next-generation strategies. J Exp Med. 2024;221:e20230903.","journal-title":"J Exp Med"},{"key":"5266_CR14","doi-asserted-by":"publisher","first-page":"9751","DOI":"10.1038\/s41467-024-54150-z","volume":"15","author":"S Li","year":"2024","unstructured":"Li S, et al. Split-design approach enhances the therapeutic efficacy of ligand-based CAR-T cells against multiple B-cell malignancies. Nat Commun. 2024;15:9751.","journal-title":"Nat Commun"},{"key":"5266_CR15","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41467-024-44873-4","volume":"15","author":"F Sun","year":"2024","unstructured":"Sun F, et al. Bispecific BCMA\/CD24 CAR-T cells control multiple myeloma growth. Nat Commun. 2024;15:615.","journal-title":"Nat Commun"},{"key":"5266_CR16","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1038\/s41467-024-47801-8","volume":"15","author":"M Shi","year":"2024","unstructured":"Shi M, et al. Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: a phase I\/II trial. Nat Commun. 2024;15:3371.","journal-title":"Nat Commun"},{"key":"5266_CR17","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1158\/0008-5472.CAN-15-0159","volume":"75","author":"X Liu","year":"2015","unstructured":"Liu X, et al. Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice. Cancer Res. 2015;75:3596\u2013607.","journal-title":"Cancer Res"},{"key":"5266_CR18","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3390\/ijms21010204","volume":"21","author":"HE Hughes-Parry","year":"2019","unstructured":"Hughes-Parry HE, Cross RS, Jenkins MR. The evolving protein engineering in the design of chimeric antigen receptor T cells. Int J Mol Sci. 2019;21:204.","journal-title":"Int J Mol Sci"},{"key":"5266_CR19","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","volume":"173","author":"JH Cho","year":"2018","unstructured":"Cho JH, Collins JJ, Wong WW. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell. 2018;173:1426\u201338.","journal-title":"Cell"},{"key":"5266_CR20","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","volume":"168","author":"WA Lim","year":"2017","unstructured":"Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell. 2017;168:724\u201340.","journal-title":"Cell"},{"key":"5266_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41571-023-00729-2","volume":"20","author":"J Yang","year":"2023","unstructured":"Yang J, Chen Y, Jing Y, Green MR, Han L. Advancing CAR T cell therapy through the use of multidimensional omics data. Nat Reviews Clin Oncol. 2023;20:211\u201328.","journal-title":"Nat Reviews Clin Oncol"},{"key":"5266_CR22","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1158\/2643-3230.BCD-23-0212","volume":"5","author":"NJ Haradhvala","year":"2024","unstructured":"Haradhvala NJ, Maus MV. Understanding mechanisms of response to CAR T-cell therapy through single-cell sequencing: insights and challenges. Blood Cancer Discovery. 2024;5:86\u20139.","journal-title":"Blood Cancer Discovery"},{"key":"5266_CR23","doi-asserted-by":"crossref","unstructured":"Meehl MM, Ward MB, Krenciute G. Mapping clinical CAR-T cells: insights from scRNA-seq. Trends Mol Med. 2026;32(7):678\u201396.","DOI":"10.1016\/j.molmed.2025.12.006"},{"key":"5266_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coi.2015.01.002","volume":"33","author":"MC Jensen","year":"2015","unstructured":"Jensen MC, Riddell SR. Designing chimeric antigen receptors to effectively and safely target tumors. Curr Opin Immunol. 2015;33:9\u201315.","journal-title":"Curr Opin Immunol"},{"key":"5266_CR25","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.coi.2021.07.002","volume":"74","author":"AC Sahillioglu","year":"2022","unstructured":"Sahillioglu AC, Schumacher T. N. Safety switches for adoptive cell therapy. Curr Opin Immunol. 2022;74:190\u20138.","journal-title":"Curr Opin Immunol"},{"key":"5266_CR26","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/leu.2010.75","volume":"24","author":"V Hoyos","year":"2010","unstructured":"Hoyos V, et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma\/leukemia effects and safety. Leukemia. 2010;24:1160\u201370.","journal-title":"Leukemia"},{"key":"5266_CR27","doi-asserted-by":"publisher","first-page":"aab4077","DOI":"10.1126\/science.aab4077","volume":"350","author":"C-Y Wu","year":"2015","unstructured":"Wu C-Y, Roybal KT, Puchner EM, Onuffer J, Lim WA. Remote control of therapeutic T cells through a small molecule\u2013gated chimeric receptor. Science. 2015;350:aab4077.","journal-title":"Science"},{"key":"5266_CR28","doi-asserted-by":"publisher","first-page":"E459","DOI":"10.1073\/pnas.1524155113","volume":"113","author":"DT Rodgers","year":"2016","unstructured":"Rodgers DT, et al. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci. 2016;113:E459\u201368.","journal-title":"Proc Natl Acad Sci"},{"key":"5266_CR29","doi-asserted-by":"publisher","first-page":"7520","DOI":"10.1002\/anie.201601902","volume":"55","author":"Y Cao","year":"2016","unstructured":"Cao Y, et al. Design of switchable chimeric antigen receptor T cells targeting breast cancer. Angew Chem Int Ed. 2016;55:7520\u20134.","journal-title":"Angew Chem Int Ed"},{"key":"5266_CR30","doi-asserted-by":"publisher","first-page":"E10898","DOI":"10.1073\/pnas.1810060115","volume":"115","author":"S Viaud","year":"2018","unstructured":"Viaud S, et al. Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory. Proc Natl Acad Sci. 2018;115:E10898\u2013906.","journal-title":"Proc Natl Acad Sci"},{"key":"5266_CR31","doi-asserted-by":"crossref","unstructured":"Darowski D, Kobold S, Jost C, Klein C. Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells. Volume 11. Taylor & Francis; 2019. pp. 621\u201331.","DOI":"10.1080\/19420862.2019.1596511"},{"key":"5266_CR32","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1136\/gutjnl-2018-316595","volume":"68","author":"D Raj","year":"2019","unstructured":"Raj D, et al. Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma. Gut. 2019;68:1052\u201364.","journal-title":"Gut"},{"key":"5266_CR33","doi-asserted-by":"publisher","first-page":"12178","DOI":"10.1002\/anie.202005432","volume":"59","author":"J Qi","year":"2020","unstructured":"Qi J, et al. Chemically programmable and switchable CAR-T therapy. Angew Chem Int Ed. 2020;59:12178\u201385.","journal-title":"Angew Chem Int Ed"},{"key":"5266_CR34","doi-asserted-by":"publisher","first-page":"18870","DOI":"10.1074\/jbc.M309169200","volume":"279","author":"C Zahnd","year":"2004","unstructured":"Zahnd C, et al. Directed in vitro evolution and crystallographic analysis of a peptide-binding single chain antibody fragment (scFv) with low picomolar affinity. J Biol Chem. 2004;279:18870\u20137.","journal-title":"J Biol Chem"},{"key":"5266_CR35","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1038\/s41388-022-02416-5","volume":"41","author":"H Peng","year":"2022","unstructured":"Peng H, et al. ROR1-targeting switchable CAR-T cells for cancer therapy. Oncogene. 2022;41:4104\u201314.","journal-title":"Oncogene"},{"key":"5266_CR36","doi-asserted-by":"publisher","first-page":"965","DOI":"10.3390\/ijms26030965","volume":"26","author":"R Kitte","year":"2025","unstructured":"Kitte R, et al. Optimal chimeric antigen receptor (CAR)-mRNA for transient CAR T cell generation. Int J Mol Sci. 2025;26:965.","journal-title":"Int J Mol Sci"},{"key":"5266_CR37","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1038\/s41467-020-19486-2","volume":"11","author":"N Parayath","year":"2020","unstructured":"Parayath N, Stephan S, Koehne A, Nelson P, Stephan M. In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo. Nat Commun. 2020;11:6080.","journal-title":"Nat Commun"},{"key":"5266_CR38","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1089\/hum.2017.080","volume":"29","author":"C-F Hung","year":"2018","unstructured":"Hung C-F, et al. Development of anti-human mesothelin-targeted chimeric antigen receptor messenger RNA\u2013transfected peripheral blood lymphocytes for ovarian cancer therapy. Hum Gene Ther. 2018;29:614\u201325.","journal-title":"Hum Gene Ther"},{"key":"5266_CR39","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","volume":"23","author":"J Ren","year":"2017","unstructured":"Ren J, et al. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res. 2017;23:2255\u201366.","journal-title":"Clin Cancer Res"},{"key":"5266_CR40","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3390\/cells9040998","volume":"9","author":"T Nakazawa","year":"2020","unstructured":"Nakazawa T, et al. Effect of CRISPR\/Cas9-mediated PD-1-disrupted primary human third-generation CAR-T cells targeting EGFRvIII on in vitro human glioblastoma cell growth. Cells. 2020;9:998.","journal-title":"Cells"},{"key":"5266_CR41","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ymthe.2019.01.014","volume":"27","author":"H-X Zhang","year":"2019","unstructured":"Zhang H-X, Zhang Y, Yin H. Genome editing with mRNA encoding ZFN, TALEN, and Cas9. Mol Ther. 2019;27:735\u201346.","journal-title":"Mol Ther"},{"key":"5266_CR42","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s13287-021-02510-7","volume":"12","author":"E Razeghian","year":"2021","unstructured":"Razeghian E, et al. A deep insight into CRISPR\/Cas9 application in CAR-T cell-based tumor immunotherapies. Stem cell research therapy. 2021;12:428.","journal-title":"Stem cell research therapy"},{"key":"5266_CR43","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1038\/s41467-020-15053-x","volume":"11","author":"NS McCarty","year":"2020","unstructured":"McCarty NS, Graham AE, Studen\u00e1 L. Ledesma-Amaro, R. Multiplexed CRISPR technologies for gene editing and transcriptional regulation. Nat Commun. 2020;11:1281.","journal-title":"Nat Commun"},{"key":"5266_CR44","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s41592-019-0329-7","volume":"16","author":"X Dai","year":"2019","unstructured":"Dai X, et al. One-step generation of modular CAR-T cells with AAV\u2013Cpf1. Nat Methods. 2019;16:247\u201354.","journal-title":"Nat Methods"},{"key":"5266_CR45","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s41592-019-0329-7","volume":"16","author":"X Dai","year":"2019","unstructured":"Dai X, et al. One-step generation of modular CAR-T cells with AAV\u2013Cpf1. Nat Methods. 2019;16:247\u201354.","journal-title":"Nat Methods"},{"key":"5266_CR46","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1182\/blood.2023020973","volume":"143","author":"J Kath","year":"2024","unstructured":"Kath J, et al. Integration of \u03b6-deficient CARs into the CD3 \u03b6 gene conveys potent cytotoxicity in T and NK cells. Blood. 2024;143:2599\u2013611.","journal-title":"Blood"},{"key":"5266_CR47","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMp2400209","volume":"390","author":"N Verdun","year":"2024","unstructured":"Verdun N, Marks P. Secondary cancers after chimeric antigen receptor T-cell therapy. N Engl J Med. 2024;390:584\u20136.","journal-title":"N Engl J Med"},{"key":"5266_CR48","doi-asserted-by":"publisher","first-page":"7705","DOI":"10.3390\/cimb45100486","volume":"45","author":"PD Mo\u00e7o","year":"2023","unstructured":"Mo\u00e7o PD, Farn\u00f3s O, Sharon D, Kamen AA. Targeted delivery of chimeric antigen receptor into T cells via CRISPR-mediated homology-directed repair with a dual-AAV6 transduction system. Curr Issues Mol Biol. 2023;45:7705\u201320.","journal-title":"Curr Issues Mol Biol"},{"key":"5266_CR49","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.cell.2020.03.039","volume":"181","author":"TL Roth","year":"2020","unstructured":"Roth TL, et al. Pooled knockin targeting for genome engineering of cellular immunotherapies. Cell. 2020;181:728\u201344.","journal-title":"Cell"},{"key":"5266_CR50","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/s11684-017-0543-6","volume":"11","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, et al. CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells. Front Med. 2017;11:554\u201362.","journal-title":"Front Med"},{"key":"5266_CR51","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00280-019-03800-x","volume":"83","author":"W Zhang","year":"2019","unstructured":"Zhang W, et al. Disruption of CTLA-4 expression on peripheral blood CD8\u2009+\u2009T cell enhances anti-tumor efficacy in bladder cancer. Cancer Chemother Pharmacol. 2019;83:911\u201320.","journal-title":"Cancer Chemother Pharmacol"},{"key":"5266_CR52","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","volume":"30","author":"X He","year":"2020","unstructured":"He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020;30:660\u20139.","journal-title":"Cell Res"},{"key":"5266_CR53","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/s41573-020-0084-6","volume":"19","author":"EM Porto","year":"2020","unstructured":"Porto EM, Komor AC, Slaymaker IM, Yeo GW. Base editing: advances and therapeutic opportunities. Nat Rev Drug Discovery. 2020;19:839\u201359.","journal-title":"Nat Rev Drug Discovery"},{"key":"5266_CR54","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","volume":"38","author":"AV Anzalone","year":"2020","unstructured":"Anzalone AV, Koblan LW, Liu DR. Genome editing with CRISPR\u2013Cas nucleases, base editors, transposases and prime editors. Nat Biotechnol. 2020;38:824\u201344.","journal-title":"Nat Biotechnol"},{"key":"5266_CR55","doi-asserted-by":"publisher","first-page":"5222","DOI":"10.1038\/s41467-019-13007-6","volume":"10","author":"BR Webber","year":"2019","unstructured":"Webber BR, et al. Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors. Nat Commun. 2019;10:5222.","journal-title":"Nat Commun"},{"key":"5266_CR56","doi-asserted-by":"publisher","unstructured":"Pomeroy EJ, Anzalone AV, Podracky CJ, Bloch NB, Chang R, Dwivedi AA, Laoharawee K, et al. Multiplex prime editing and PASSIGE TM for non-viral generation of an allogeneic CAR-T cell product. Blood. 2023;142:4803. https:\/\/doi.org\/10.1182\/blood-2023-181869","DOI":"10.1182\/blood-2023-181869"},{"key":"5266_CR57","doi-asserted-by":"publisher","first-page":"878209","DOI":"10.3389\/fimmu.2022.878209","volume":"13","author":"G L\u00f3pez-Cantillo","year":"2022","unstructured":"L\u00f3pez-Cantillo G, Urue\u00f1a C, Camacho BA. Ram\u00edrez-Segura, C. CAR-T cell performance: how to improve their persistence? Front Immunol. 2022;13:878209.","journal-title":"Front Immunol"},{"key":"5266_CR58","doi-asserted-by":"publisher","first-page":"1063454","DOI":"10.3389\/fimmu.2023.1063454","volume":"14","author":"Y Kong","year":"2023","unstructured":"Kong Y, Tang L, You Y, Li Q, Zhu X. Analysis of causes for poor persistence of CAR-T cell therapy in vivo. Front Immunol. 2023;14:1063454.","journal-title":"Front Immunol"},{"key":"5266_CR59","doi-asserted-by":"crossref","unstructured":"Gattinoni L, Inchingolo G, Harrer DC, Susana A, Puccio S, Slavkovic-Lukic D, Natrakul DA, Strieder N, Heuser-Loy C, Baldwin JG, Fioravanti J. Distinct in vivo dynamics of donor-derived stem cell memory CAR T cells post-allogeneic HSCT relapse. Cell. 2026;189(12):3686\u2013700.","DOI":"10.1016\/j.cell.2026.03.047"},{"key":"5266_CR60","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1182\/bloodadvances.2024015346","volume":"9","author":"A Riedel","year":"2025","unstructured":"Riedel A, et al. Immunological consequences of CAR T-cell therapy: an analysis of infectious complications and immune reconstitution. Blood Adv. 2025;9:3149\u201358.","journal-title":"Blood Adv"},{"key":"5266_CR61","doi-asserted-by":"publisher","first-page":"1613878","DOI":"10.3389\/fimmu.2025.1613878","volume":"16","author":"D Wu","year":"2025","unstructured":"Wu D, et al. CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon. Front Immunol. 2025;16:1613878.","journal-title":"Front Immunol"},{"key":"5266_CR62","doi-asserted-by":"publisher","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","volume":"367","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer EA, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367:eaba7365.","journal-title":"Science"},{"key":"5266_CR63","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1016\/j.ymthe.2018.06.002","volume":"26","author":"MK Cromer","year":"2018","unstructured":"Cromer MK, et al. Global transcriptional response to CRISPR\/Cas9-AAV6-based genome editing in CD34\u2009+\u2009hematopoietic stem and progenitor cells. Mol Ther. 2018;26:2431\u201342.","journal-title":"Mol Ther"},{"key":"5266_CR64","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nbt.4192","volume":"36","author":"M Kosicki","year":"2018","unstructured":"Kosicki M, Tomberg K, Bradley A. Repair of double-strand breaks induced by CRISPR\u2013Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol. 2018;36:765\u201371.","journal-title":"Nat Biotechnol"},{"key":"5266_CR65","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/s41588-021-00838-7","volume":"53","author":"ML Leibowitz","year":"2021","unstructured":"Leibowitz ML, et al. Chromothripsis as an on-target consequence of CRISPR\u2013Cas9 genome editing. Nat Genet. 2021;53:895\u2013905.","journal-title":"Nat Genet"},{"key":"5266_CR66","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41467-019-09006-2","volume":"10","author":"G Cullot","year":"2019","unstructured":"Cullot G, et al. CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations. Nat Commun. 2019;10:1136.","journal-title":"Nat Commun"},{"key":"5266_CR67","doi-asserted-by":"publisher","first-page":"e2004832117","DOI":"10.1073\/pnas.2004832117","volume":"118","author":"G Alanis-Lobato","year":"2021","unstructured":"Alanis-Lobato G, et al. Frequent loss of heterozygosity in CRISPR-Cas9\u2013edited early human embryos. Proc Natl Acad Sci. 2021;118:e2004832117.","journal-title":"Proc Natl Acad Sci"},{"key":"5266_CR68","doi-asserted-by":"publisher","unstructured":"Murad JP, Christian L, Rosa R, Ren Y, Buckley AJ, Lee EH, Lopez LS, Park AK, Yang J, Yamaguchi Y, Trac C. Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery. Nat Biomed Eng. 2026;10(4):613\u201329. https:\/\/doi.org\/10.1038\/s41551-025-01509-2","DOI":"10.1038\/s41551-025-01509-2"},{"key":"5266_CR69","doi-asserted-by":"publisher","first-page":"1643941","DOI":"10.3389\/fimmu.2025.1643941","volume":"16","author":"DD Yang","year":"2025","unstructured":"Yang DD, Macmorland W, Arnold J. N. Current strategies for armoring chimeric antigen receptor T-cells to overcome barriers of the solid tumor microenvironment. Front Immunol. 2025;16:1643941.","journal-title":"Front Immunol"},{"key":"5266_CR70","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","volume":"26","author":"CC Kloss","year":"2018","unstructured":"Kloss CC, et al. Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol Ther. 2018;26:1855\u201366.","journal-title":"Mol Ther"},{"key":"5266_CR71","doi-asserted-by":"publisher","first-page":"832645","DOI":"10.3389\/fimmu.2022.832645","volume":"13","author":"LM Alabanza","year":"2022","unstructured":"Alabanza LM, et al. Armored BCMA CAR T cells eliminate multiple myeloma and are resistant to the suppressive effects of TGF-\u03b2. Front Immunol. 2022;13:832645.","journal-title":"Front Immunol"},{"key":"5266_CR72","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nri1001","volume":"3","author":"G Trinchieri","year":"2003","unstructured":"Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3:133\u201346.","journal-title":"Nat Rev Immunol"},{"key":"5266_CR73","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/cdd.2014.134","volume":"22","author":"S Tugues","year":"2015","unstructured":"Tugues S, et al. New insights into IL-12-mediated tumor suppression. Cell Death Differentiation. 2015;22:237\u201346.","journal-title":"Cell Death Differentiation"},{"key":"5266_CR74","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1084\/jem.20151159","volume":"212","author":"MD Buck","year":"2015","unstructured":"Buck MD, O\u2019sullivan D, Pearce E. L. T cell metabolism drives immunity. J Exp Med. 2015;212:1345.","journal-title":"J Exp Med"},{"key":"5266_CR75","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","volume":"36","author":"K Adachi","year":"2018","unstructured":"Adachi K, et al. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol. 2018;36:346\u201351.","journal-title":"Nat Biotechnol"},{"key":"5266_CR76","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/JCI83092","volume":"126","author":"L Cherkassky","year":"2016","unstructured":"Cherkassky L, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Investig. 2016;126:3130\u201344.","journal-title":"J Clin Investig"},{"key":"5266_CR77","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","volume":"36","author":"S Rafiq","year":"2018","unstructured":"Rafiq S, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36:847\u201356.","journal-title":"Nat Biotechnol"},{"key":"5266_CR78","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1126\/science.aaf2807","volume":"354","author":"KE Pauken","year":"2016","unstructured":"Pauken KE, et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science. 2016;354:1160\u20135.","journal-title":"Science"},{"key":"5266_CR79","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s40164-024-00564-w","volume":"13","author":"X Li","year":"2024","unstructured":"Li X, et al. Therapeutic targets of armored chimeric antigen receptor T cells navigating the tumor microenvironment. Experimental Hematology Oncology. 2024;13:96.","journal-title":"Experimental Hematology Oncology"},{"key":"5266_CR80","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s12032-025-02957-1","volume":"42","author":"H Bharadia","year":"2025","unstructured":"Bharadia H, et al. CAR T-cell immunotherapy as the next horizon in cancer eradication: current landscape, challenges, and future directions. Med Oncol. 2025;42:410.","journal-title":"Med Oncol"},{"key":"5266_CR81","first-page":"460","volume":"22","author":"T Zhong","year":"2025","unstructured":"Zhong T, Sun S, Zhao M, Zhang B, Xiong H. The mechanisms and clinical significance of CD8\u2009+\u2009T cell exhaustion in anti-tumor immunity. Cancer Biology Medicine. 2025;22:460\u201380.","journal-title":"Cancer Biology Medicine"},{"key":"5266_CR82","doi-asserted-by":"publisher","first-page":"1700039","DOI":"10.3389\/fimmu.2025.1700039","volume":"16","author":"C Li","year":"2025","unstructured":"Li C, Yuan Y, Wang Q, Jiang X. Epigenetic Regulation of CD8+ T Cell Exhaustion: Recent Advances and Update. Front Immunol. 2025;16:1700039.","journal-title":"Front Immunol"},{"key":"5266_CR83","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.immuni.2015.01.006","volume":"42","author":"GJ Martinez","year":"2015","unstructured":"Martinez GJ, et al. The transcription factor NFAT promotes exhaustion of activated CD8\u2009+\u2009T cells. Immunity. 2015;42:265\u201378.","journal-title":"Immunity"},{"key":"5266_CR84","doi-asserted-by":"publisher","first-page":"12410","DOI":"10.1073\/pnas.1905675116","volume":"116","author":"H Seo","year":"2019","unstructured":"Seo H, et al. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8\u2009+\u2009T cell exhaustion. Proc Natl Acad Sci. 2019;116:12410\u20135.","journal-title":"Proc Natl Acad Sci"},{"key":"5266_CR85","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41590-021-00964-8","volume":"22","author":"H Seo","year":"2021","unstructured":"Seo H, et al. BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells. Nat Immunol. 2021;22:983\u201395.","journal-title":"Nat Immunol"},{"key":"5266_CR86","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1324-y","volume":"571","author":"AC Scott","year":"2019","unstructured":"Scott AC, et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature. 2019;571:270\u20134.","journal-title":"Nature"},{"key":"5266_CR87","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nature19330","volume":"537","author":"SJ Im","year":"2016","unstructured":"Im SJ, et al. Defining CD8\u2009+\u2009T cells that provide the proliferative burst after PD-1 therapy. Nature. 2016;537:417\u201321.","journal-title":"Nature"},{"key":"5266_CR88","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller BC, et al. Subsets of exhausted CD8\u2009+\u2009T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019;20:326\u201336.","journal-title":"Nat Immunol"},{"key":"5266_CR89","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1126\/science.aae0491","volume":"354","author":"DR Sen","year":"2016","unstructured":"Sen DR, et al. The epigenetic landscape of T cell exhaustion. Science. 2016;354:1165\u20139.","journal-title":"Science"},{"key":"5266_CR90","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","volume":"52","author":"J-C Beltra","year":"2020","unstructured":"Beltra J-C, et al. Developmental relationships of four exhausted CD8\u2009+\u2009T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms. Immunity. 2020;52:825\u201341.","journal-title":"Immunity"},{"key":"5266_CR91","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.ymthe.2024.04.004","volume":"32","author":"T Ahn","year":"2024","unstructured":"Ahn T, Bae E-A, Seo H. Decoding and overcoming T cell exhaustion: Epigenetic and transcriptional dynamics in CAR-T cells against solid tumors. Mol Ther. 2024;32:1617\u201327.","journal-title":"Mol Ther"},{"key":"5266_CR92","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nature22367","volume":"545","author":"M Philip","year":"2017","unstructured":"Philip M, et al. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature. 2017;545:452\u20136.","journal-title":"Nature"},{"key":"5266_CR93","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.3390\/cancers15071935","volume":"15","author":"M Alvanou","year":"2023","unstructured":"Alvanou M, et al. Empowering the potential of CAR-T cell immunotherapies by epigenetic reprogramming. Cancers. 2023;15:1935.","journal-title":"Cancers"},{"key":"5266_CR94","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.3390\/cancers13061229","volume":"13","author":"SM Rad","year":"2021","unstructured":"Rad SM. Metabolic and mitochondrial functioning in chimeric antigen receptor (CAR)\u2014T cells. Cancers. 2021;13:1229.","journal-title":"Cancers"},{"key":"5266_CR95","doi-asserted-by":"publisher","first-page":"5442","DOI":"10.3390\/cancers14215442","volume":"14","author":"J Rial Saborido","year":"2022","unstructured":"Rial Saborido J, V\u00f6lkl S, Aigner M, Mackensen A, Mougiakakos D. Role of CAR T cell metabolism for therapeutic efficacy. Cancers. 2022;14:5442.","journal-title":"Cancers"},{"key":"5266_CR96","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/ni.3415","volume":"17","author":"C-H Chang","year":"2016","unstructured":"Chang C-H, Pearce EL. Emerging concepts of T cell metabolism as a target of immunotherapy. Nat Immunol. 2016;17:364\u20138.","journal-title":"Nat Immunol"},{"key":"5266_CR97","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.cmet.2022.12.003","volume":"35","author":"C-H Tsai","year":"2023","unstructured":"Tsai C-H, et al. Immunoediting instructs tumor metabolic reprogramming to support immune evasion. Cell Metabol. 2023;35:118\u201333.","journal-title":"Cell Metabol"},{"key":"5266_CR98","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1038\/s41590-024-01918-6","volume":"25","author":"D Soll","year":"2024","unstructured":"Soll D, et al. Sodium chloride in the tumor microenvironment enhances T cell metabolic fitness and cytotoxicity. Nat Immunol. 2024;25:1830\u201344.","journal-title":"Nat Immunol"},{"key":"5266_CR99","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.it.2015.02.007","volume":"36","author":"PJ Siska","year":"2015","unstructured":"Siska PJ, Rathmell J. C. T cell metabolic fitness in antitumor immunity. Trends Immunol. 2015;36:257\u201364.","journal-title":"Trends Immunol"},{"key":"5266_CR100","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ccell.2017.08.004","volume":"32","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, et al. Enhancing CD8\u2009+\u2009T cell fatty acid catabolism within a metabolically challenging tumor microenvironment increases the efficacy of melanoma immunotherapy. Cancer Cell. 2017;32:377\u201391.","journal-title":"Cancer Cell"},{"key":"5266_CR101","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s42255-024-00976-2","volume":"6","author":"SJ McPhedran","year":"2024","unstructured":"McPhedran SJ, Carleton GA, Lum JJ. Metabolic engineering for optimized CAR-T cell therapy. Nat Metabolism. 2024;6:396\u2013408.","journal-title":"Nat Metabolism"},{"key":"5266_CR102","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.cell.2017.04.004","volume":"169","author":"MD Buck","year":"2017","unstructured":"Buck MD, Sowell RT, Kaech SM, Pearce EL. Metabolic instruction of immunity. Cell. 2017;169:570\u201386.","journal-title":"Cell"},{"key":"5266_CR103","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1038\/s41590-024-01999-3","volume":"25","author":"RM Peralta","year":"2024","unstructured":"Peralta RM, et al. Dysfunction of exhausted T cells is enforced by MCT11-mediated lactate metabolism. Nat Immunol. 2024;25:2297\u2013307.","journal-title":"Nat Immunol"},{"key":"5266_CR104","doi-asserted-by":"publisher","first-page":"8658","DOI":"10.1038\/s41467-024-52666-y","volume":"15","author":"JA Guerrero","year":"2024","unstructured":"Guerrero JA, et al. GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency. Nat Commun. 2024;15:8658.","journal-title":"Nat Commun"},{"key":"5266_CR105","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/cyto.a.22271","volume":"83","author":"R Finck","year":"2013","unstructured":"Finck R, et al. Normalization of mass cytometry data with bead standards. Cytometry Part A. 2013;83:483\u201394.","journal-title":"Cytometry Part A"},{"key":"5266_CR106","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nm.4108","volume":"22","author":"SG Deeks","year":"2016","unstructured":"Deeks SG, et al. International AIDS Society global scientific strategy: towards an HIV cure 2016. Nat Med. 2016;22:839\u201350.","journal-title":"Nat Med"},{"key":"5266_CR107","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8:1219\u201326.","journal-title":"Cancer Discov"},{"key":"5266_CR108","doi-asserted-by":"publisher","first-page":"a007054","DOI":"10.1101\/cshperspect.a007054","volume":"2","author":"B Walker","year":"2012","unstructured":"Walker B, McMichael A. The T-cell response to HIV. Cold Spring Harbor Perspect Med. 2012;2:a007054.","journal-title":"Cold Spring Harbor Perspect Med"},{"key":"5266_CR109","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/nature03724","volume":"435","author":"CC Goodnow","year":"2005","unstructured":"Goodnow CC, Sprent J, de St Groth BF, Vinuesa CG. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature. 2005;435:590\u20137.","journal-title":"Nature"},{"key":"5266_CR110","doi-asserted-by":"crossref","unstructured":"Liu B, Zhang W, Xia B, Jing S, Du Y, Zou F, Li R, Lu L, Chen S, Li Y, Hu Q. Broadly neutralizing antibody\u2013derived CAR T cells reduce viral reservoir in individuals infected with HIV-1. J Clin Invest. 2021;131(19).","DOI":"10.1172\/JCI150211"},{"key":"5266_CR111","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1126\/science.abc1855","volume":"371","author":"RA Hernandez-Lopez","year":"2021","unstructured":"Hernandez-Lopez RA, et al. T cell circuits that sense antigen density with an ultrasensitive threshold. Science. 2021;371:1166\u201371.","journal-title":"Science"},{"key":"5266_CR112","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1172\/JCI78089","volume":"125","author":"JA Bluestone","year":"2015","unstructured":"Bluestone JA, Bour-Jordan H, Cheng M, Anderson. M. T cells in the control of organ-specific autoimmunity. J Clin Investig. 2015;125:2250\u201360.","journal-title":"J Clin Investig"},{"key":"5266_CR113","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1172\/JCI82771","volume":"126","author":"KG MacDonald","year":"2016","unstructured":"MacDonald KG, et al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J Clin Investig. 2016;126:1413\u201324.","journal-title":"J Clin Investig"},{"key":"5266_CR114","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","volume":"164","author":"KT Roybal","year":"2016","unstructured":"Roybal KT, et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell. 2016;164:770\u20139.","journal-title":"Cell"},{"key":"5266_CR115","doi-asserted-by":"publisher","first-page":"640082","DOI":"10.3389\/fimmu.2021.640082","volume":"12","author":"D Mart\u00ednez Bedoya","year":"2021","unstructured":"Mart\u00ednez Bedoya D, Dutoit V, Migliorini D, Allogeneic. CAR T cells: an alternative to overcome challenges of CAR T cell therapy in glioblastoma. Front Immunol. 2021;12:640082.","journal-title":"Front Immunol"},{"key":"5266_CR116","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/S0140-6736(20)30167-7","volume":"395","author":"B Sawitzki","year":"2020","unstructured":"Sawitzki B, et al. Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1\/2A trials. Lancet. 2020;395:1627\u201339.","journal-title":"Lancet"},{"key":"5266_CR117","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541\u201350.","journal-title":"Nat Med"},{"key":"5266_CR118","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.ymthe.2016.12.023","volume":"25","author":"M Hale","year":"2017","unstructured":"Hale M, et al. Engineering HIV-resistant, anti-HIV chimeric antigen receptor T cells. Mol Ther. 2017;25:570\u20139.","journal-title":"Mol Ther"},{"key":"5266_CR119","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/imm.13888","volume":"174","author":"S Zhu","year":"2025","unstructured":"Zhu S, Hu J, Lin J, Wang C, Wang E. Co-Expression of Dominant\u2010Negative TGF\u2010\u03b2 Receptor 2 Enhances the Therapeutic Efficacy of Novel TREM1\/DAP12\u2010BB\u2010Based CAR\u2010T Cells in Solid Tumours. Immunology. 2025;174:310\u201321.","journal-title":"Immunology"},{"key":"5266_CR120","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.immuni.2019.01.020","volume":"50","author":"JB Wing","year":"2019","unstructured":"Wing JB, Tanaka A, Sakaguchi S. Human FOXP3\u2009+\u2009regulatory T cell heterogeneity and function in autoimmunity and cancer. Immunity. 2019;50:302\u201316.","journal-title":"Immunity"},{"key":"5266_CR121","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn RC, et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature. 2019;576:293\u2013300.","journal-title":"Nature"},{"key":"5266_CR122","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1126\/science.1079490","volume":"299","author":"S Hori","year":"2003","unstructured":"Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057\u201361.","journal-title":"Science"},{"key":"5266_CR123","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1158\/1538-7445.AM2017-654","volume":"77","author":"D Sen","year":"2017","unstructured":"Sen D. The epigenetic landscape of T cell exhaustion. Cancer Res. 2017;77:654\u2013654.","journal-title":"Cancer Res"},{"key":"5266_CR124","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41590-020-00834-9","volume":"22","author":"NE Scharping","year":"2021","unstructured":"Scharping NE, et al. Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nat Immunol. 2021;22:205\u201315.","journal-title":"Nat Immunol"},{"key":"5266_CR125","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/ni.3466","volume":"17","author":"R Newton","year":"2016","unstructured":"Newton R, Priyadharshini B, Turka LA. Immunometabolism of regulatory T cells. Nat Immunol. 2016;17:618\u201325.","journal-title":"Nat Immunol"},{"key":"5266_CR126","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24:563\u201371.","journal-title":"Nat Med"},{"key":"5266_CR127","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.3390\/jcm10051004","volume":"10","author":"S Audia","year":"2021","unstructured":"Audia S, Bonnotte B. Emerging therapies in immune thrombocytopenia. J Clin Med. 2021;10:1004.","journal-title":"J Clin Med"},{"key":"5266_CR128","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, et al. Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities. Nat reviews Clin Oncol. 2018;15:47\u201362.","journal-title":"Nat reviews Clin Oncol"},{"key":"5266_CR129","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1126\/science.1255512","volume":"345","author":"DH Barouch","year":"2014","unstructured":"Barouch DH, Deeks SG. Immunologic strategies for HIV-1 remission and eradication. Science. 2014;345:169\u201374.","journal-title":"Science"},{"key":"5266_CR130","doi-asserted-by":"publisher","unstructured":"Sakaguchi S. Regulatory T cells: history and perspective. In: Kassiotis G, Liston A, editors. Regulatory T cells. Methods in molecular biology, vol 707. Totowa, NJ: Humana Press; 2011. https:\/\/doi.org\/10.1007\/978-1-61737-979-6_1.","DOI":"10.1007\/978-1-61737-979-6_1"},{"key":"5266_CR131","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/COH.0000000000000858","volume":"19","author":"H Su","year":"2024","unstructured":"Su H, Mueller A, Goldstein H. Recent advances on anti-HIV chimeric antigen receptor-T-cell treatment to provide sustained HIV remission. Curr Opin HIV AIDS. 2024;19:169\u201378.","journal-title":"Curr Opin HIV AIDS"},{"key":"5266_CR132","doi-asserted-by":"crossref","unstructured":"Mu W, Tomer S, Harding J, Kedia N, Rezek V, Cook E, Patankar V, Carrillo MA, Martin H, Ng H, Wang L. Rapamycin enhances CAR-T control of HIV replication and reservoir elimination in vivo. J Clin Invest. 2025;135(7).","DOI":"10.1172\/JCI185489"},{"key":"5266_CR133","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3389\/fcimb.2020.00410","volume":"10","author":"W Mu","year":"2020","unstructured":"Mu W, Carrillo MA, Kitchen SG. Engineering CAR T cells to target the HIV reservoir. Front Cell Infect Microbiol. 2020;10:410.","journal-title":"Front Cell Infect Microbiol"},{"key":"5266_CR134","doi-asserted-by":"crossref","unstructured":"Han Q, Zhang X, Chen L, Zhang Y. Chimeric antigen receptor T\u2011cell therapy in chronic viral infections: a review. J Transl Med. 2026:24(1);167.","DOI":"10.1186\/s12967-025-07582-0"},{"key":"5266_CR135","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/ID9.0000000000000129","volume":"4","author":"X Wang","year":"2024","unstructured":"Wang X, Liu J, Hao F, Ajavavarakula T, Shi X. CAR-T Therapy in HIV: Pioneering Advances and Navigating Challenges. Infectious Diseases Immunity. 2024;4:194\u2013205.","journal-title":"Infectious Diseases Immunity"},{"key":"5266_CR136","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/S2352-3018(18)30039-0","volume":"5","author":"MC Pitman","year":"2018","unstructured":"Pitman MC, Lau JS, McMahon JH, Lewin SR. Barriers and strategies to achieve a cure for HIV. Lancet HIV. 2018;5:e317\u201328.","journal-title":"Lancet HIV"},{"key":"5266_CR137","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1038\/s41591-021-01590-5","volume":"27","author":"SG Deeks","year":"2021","unstructured":"Deeks SG, et al. Research priorities for an HIV cure: international AIDS society global scientific strategy 2021. Nat Med. 2021;27:2085\u201398.","journal-title":"Nat Med"},{"key":"5266_CR138","doi-asserted-by":"publisher","first-page":"eaav5685","DOI":"10.1126\/scitranslmed.aav5685","volume":"11","author":"K Anthony-Gonda","year":"2019","unstructured":"Anthony-Gonda K, et al. Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model. Sci Transl Med. 2019;11:eaav5685.","journal-title":"Sci Transl Med"},{"key":"5266_CR139","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/s41577-025-01136-7","volume":"25","author":"DA Kulpa","year":"2025","unstructured":"Kulpa DA, Paiardini M, Silvestri G. Immune-mediated strategies to solving the HIV reservoir problem. Nat Rev Immunol. 2025;25:542\u201353.","journal-title":"Nat Rev Immunol"},{"key":"5266_CR140","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3389\/fcimb.2020.00410","volume":"10","author":"W Mu","year":"2020","unstructured":"Mu W, Carrillo MA, Kitchen SG. Engineering CAR T cells to target the HIV reservoir. Front Cell Infect Microbiol. 2020;10:410.","journal-title":"Front Cell Infect Microbiol"},{"key":"5266_CR141","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.3390\/v17121615","volume":"17","author":"M-D Padurariu-Covit","year":"2025","unstructured":"Padurariu-Covit M-D, et al. CAR-T Cell Therapy for HIV Cure: Current Challenges, Advances and Future Directions. Viruses. 2025;17:1615.","journal-title":"Viruses"},{"key":"5266_CR142","doi-asserted-by":"publisher","first-page":"e1006613","DOI":"10.1371\/journal.ppat.1006613","volume":"13","author":"RS Leibman","year":"2017","unstructured":"Leibman RS, et al. Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor. PLoS Pathog. 2017;13:e1006613.","journal-title":"PLoS Pathog"},{"key":"5266_CR143","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.immuni.2018.04.030","volume":"48","author":"S Sengupta","year":"2018","unstructured":"Sengupta S, Siliciano RF. Targeting the latent reservoir for HIV-1. Immunity. 2018;48:872\u201395.","journal-title":"Immunity"},{"key":"5266_CR144","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41590-022-01371-3","volume":"24","author":"VH Wu","year":"2023","unstructured":"Wu VH, et al. Profound phenotypic and epigenetic heterogeneity of the HIV-1-infected CD4\u2009+\u2009T cell reservoir. Nat Immunol. 2023;24:359\u201370.","journal-title":"Nat Immunol"},{"key":"5266_CR145","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41586-022-05538-8","volume":"614","author":"W Sun","year":"2023","unstructured":"Sun W, et al. Phenotypic signatures of immune selection in HIV-1 reservoir cells. Nature. 2023;614:309\u201317.","journal-title":"Nature"},{"key":"5266_CR146","doi-asserted-by":"crossref","unstructured":"Newick K, Moon E, Albelda SM. Chimeric antigen receptor T-cell therapy for solid tumors. Mol Ther Oncolytics. 2016;3.","DOI":"10.1038\/mto.2016.6"},{"key":"5266_CR147","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8:1219\u201326.","journal-title":"Cancer Discov"},{"key":"5266_CR148","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s41586-025-08657-0","volume":"640","author":"K Perica","year":"2025","unstructured":"Perica K, et al. HIV immune evasin Nef enhances allogeneic CAR T cell potency. Nature. 2025;640:793\u2013801.","journal-title":"Nature"},{"key":"5266_CR149","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s41586-025-08657-0","volume":"640","author":"K Perica","year":"2025","unstructured":"Perica K, et al. HIV immune evasin Nef enhances allogeneic CAR T cell potency. Nature. 2025;640:793\u2013801.","journal-title":"Nature"},{"key":"5266_CR150","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.immuni.2007.08.010","volume":"27","author":"SG Deeks","year":"2007","unstructured":"Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity. 2007;27:406\u201316.","journal-title":"Immunity"},{"key":"5266_CR151","doi-asserted-by":"crossref","unstructured":"Mu W, Tomer S, Harding J, Kedia N, Rezek V, Cook E, Patankar V, Carrillo MA, Martin H, Ng H, Wang L. Rapamycin enhances CAR-T control of HIV replication and reservoir elimination in vivo. J Clin Invest. 2025;135(7).","DOI":"10.1172\/JCI185489"},{"key":"5266_CR152","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S0140-6736(13)61809-7","volume":"382","author":"SG Deeks","year":"2013","unstructured":"Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. lancet. 2013;382:1525\u201333.","journal-title":"lancet"},{"key":"5266_CR153","doi-asserted-by":"publisher","first-page":"aaf6517","DOI":"10.1126\/science.aaf6517","volume":"353","author":"DM Margolis","year":"2016","unstructured":"Margolis DM, Garcia JV, Hazuda DJ, Haynes BF. Latency reversal and viral clearance to cure HIV-1. Science. 2016;353:aaf6517.","journal-title":"Science"},{"key":"5266_CR154","doi-asserted-by":"crossref","unstructured":"Liu B, Zhang W, Xia B, Jing S, Du Y, Zou F, Li R, Lu L, Chen S, Li Y, Hu Q. Broadly neutralizing antibody\u2013derived CAR T cells reduce viral reservoir in individuals infected with HIV-1. J Clin Invest. 2021;131(19).","DOI":"10.1172\/JCI150211"},{"key":"5266_CR155","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1053\/j.gastro.2013.04.047","volume":"145","author":"K Krebs","year":"2013","unstructured":"Krebs K, et al. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology. 2013;145:456\u201365.","journal-title":"Gastroenterology"},{"key":"5266_CR156","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","volume":"24","author":"JB Chung","year":"2024","unstructured":"Chung JB, Brudno JN, Borie D, Kochenderfer J. N. Chimeric antigen receptor T cell therapy for autoimmune disease. Nat Rev Immunol. 2024;24:830\u201345.","journal-title":"Nat Rev Immunol"},{"key":"5266_CR157","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.3389\/fimmu.2020.01608","volume":"11","author":"YR Mohseni","year":"2020","unstructured":"Mohseni YR, et al. The future of regulatory T cell therapy: promises and challenges of implementing CAR technology. Front Immunol. 2020;11:1608.","journal-title":"Front Immunol"},{"key":"5266_CR158","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41573-019-0041-4","volume":"18","author":"LM Ferreira","year":"2019","unstructured":"Ferreira LM, Muller YD, Bluestone JA, Tang Q. Next-generation regulatory T cell therapy. Nat Rev Drug Discovery. 2019;18:749\u201369.","journal-title":"Nat Rev Drug Discovery"},{"key":"5266_CR159","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1742-2094-9-112","volume":"9","author":"M Fransson","year":"2012","unstructured":"Fransson M, et al. CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery. J Neuroinflamm. 2012;9:112.","journal-title":"J Neuroinflamm"},{"key":"5266_CR160","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1126\/science.aau2688","volume":"362","author":"JA Bluestone","year":"2018","unstructured":"Bluestone JA, Tang Q. Treg cells\u2014the next frontier of cell therapy. Science. 2018;362:154\u20135.","journal-title":"Science"},{"key":"5266_CR161","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.coi.2015.05.005","volume":"35","author":"S Kontos","year":"2015","unstructured":"Kontos S, Grimm AJ, Hubbell JA. Engineering antigen-specific immunological tolerance. Curr Opin Immunol. 2015;35:80\u20138.","journal-title":"Curr Opin Immunol"},{"key":"5266_CR162","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.3389\/fimmu.2018.02359","volume":"9","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, et al. Chimeric antigen receptor (CAR) Treg: a promising approach to inducing immunological tolerance. Front Immunol. 2018;9:2359.","journal-title":"Front Immunol"},{"key":"5266_CR163","doi-asserted-by":"publisher","first-page":"103057","DOI":"10.1016\/j.jaut.2023.103057","volume":"138","author":"P Henschel","year":"2023","unstructured":"Henschel P, et al. Supraphysiological FOXP3 expression in human CAR-Tregs results in improved stability, efficacy, and safety of CAR-Treg products for clinical application. J Autoimmun. 2023;138:103057.","journal-title":"J Autoimmun"},{"key":"5266_CR164","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/jleuko\/qiae049","volume":"116","author":"E Contreras-Castillo","year":"2024","unstructured":"Contreras-Castillo E, Garc\u00eda-Rasilla VY, Garc\u00eda-Pati\u00f1o MG, Licona-Lim\u00f3n P. Stability and plasticity of regulatory T cells in health and disease. J Leukoc Biol. 2024;116:33\u201353.","journal-title":"J Leukoc Biol"},{"key":"5266_CR165","doi-asserted-by":"crossref","unstructured":"Feng J, et al. Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial. Nat Med. 2025;1\u201312.","DOI":"10.1038\/s41591-025-03937-8"},{"key":"5266_CR166","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12016-025-09114-6","volume":"68","author":"A Matarneh","year":"2025","unstructured":"Matarneh A, et al. Chimeric Antigen Receptor T Cell Therapy in Systemic Lupus Erythematosus: Mechanisms, Clinical Advances, and Future Directions a Comprehensive Review. Clinical Reviews Allergy Immunology. 2025;68:103.","journal-title":"Clinical Reviews Allergy Immunology"},{"key":"5266_CR167","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","volume":"20","author":"G Schett","year":"2024","unstructured":"Schett G, et al. Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nat Rev Rheumatol. 2024;20:531\u201344.","journal-title":"Nat Rev Rheumatol"},{"key":"5266_CR168","doi-asserted-by":"publisher","first-page":"1613878","DOI":"10.3389\/fimmu.2025.1613878","volume":"16","author":"D Wu","year":"2025","unstructured":"Wu D, et al. CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon. Front Immunol. 2025;16:1613878.","journal-title":"Front Immunol"},{"key":"5266_CR169","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.3389\/fimmu.2017.01460","volume":"8","author":"NA Dawson","year":"2017","unstructured":"Dawson NA, Vent-Schmidt J, Levings MK. Engineered tolerance: tailoring development, function, and antigen-specificity of regulatory T cells. Front Immunol. 2017;8:1460.","journal-title":"Front Immunol"},{"key":"5266_CR170","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1016\/j.immuni.2024.10.011","volume":"57","author":"G Schett","year":"2024","unstructured":"Schett G, June CH. CAR T cells in autoimmune disease: On the road to remission. Immunity. 2024;57:2705\u20139.","journal-title":"Immunity"},{"key":"5266_CR171","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28:2124\u201332.","journal-title":"Nat Med"},{"key":"5266_CR172","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1182\/blood.2024025413","volume":"145","author":"D Mougiakakos","year":"2025","unstructured":"Mougiakakos D, Meyer EH, Schett G. CAR T cells in autoimmunity: game changer or stepping stone? Blood. 2025;145:1841\u20139.","journal-title":"Blood"},{"key":"5266_CR173","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Kochenderfer JN. Current understanding and management of CAR T cell-associated toxicities. Nat Reviews Clin Oncol. 2024;21:501\u201321.","journal-title":"Nat Reviews Clin Oncol"},{"key":"5266_CR174","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"A Di Stasi","year":"2011","unstructured":"Di Stasi A, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365:1673\u201383.","journal-title":"N Engl J Med"},{"key":"5266_CR175","doi-asserted-by":"publisher","first-page":"eadj6251","DOI":"10.1126\/sciadv.adj6251","volume":"10","author":"L Lu","year":"2024","unstructured":"Lu L, Xie M, Yang B, Zhao W, Cao J. Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control. Sci Adv. 2024;10:eadj6251.","journal-title":"Sci Adv"},{"key":"5266_CR176","doi-asserted-by":"publisher","first-page":"eabd8836","DOI":"10.1126\/scitranslmed.abd8836","volume":"13","author":"A Hyrenius-Wittsten","year":"2021","unstructured":"Hyrenius-Wittsten A, et al. SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. Sci Transl Med. 2021;13:eabd8836.","journal-title":"Sci Transl Med"},{"key":"5266_CR177","doi-asserted-by":"publisher","first-page":"C1473","DOI":"10.1152\/ajpcell.00659.2024","volume":"328","author":"L Song","year":"2025","unstructured":"Song L, Zhang Q, Sui H, Gao C, Jiang Z. Recent advances in synthetic Notch receptors for biomedical application. Am J Physiology-Cell Physiol. 2025;328:C1473\u201386.","journal-title":"Am J Physiology-Cell Physiol"},{"key":"5266_CR178","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp S, Mufti G, Poirot L. Off-the-shelf\u2019allogeneic CAR T cells: development and challenges. Nat Rev Drug Discovery. 2020;19:185\u201399.","journal-title":"Nat Rev Drug Discovery"},{"key":"5266_CR179","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.omtm.2020.12.008","volume":"20","author":"J Alzubi","year":"2021","unstructured":"Alzubi J, et al. Automated generation of gene-edited CAR T cells at clinical scale. Molecular Therapy Methods Clinical Development. 2021;20:379\u201388.","journal-title":"Molecular Therapy Methods Clinical Development"},{"key":"5266_CR180","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1182\/blood.2022016204","volume":"141","author":"W Qasim","year":"2023","unstructured":"Qasim W. Genome-edited allogeneic donor universal chimeric antigen receptor T cells. Blood. 2023;141:835\u201345.","journal-title":"Blood"},{"key":"5266_CR181","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s40364-023-00509-1","volume":"11","author":"H Dabiri","year":"2023","unstructured":"Dabiri H, et al. Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies. Biomark Res. 2023;11:67.","journal-title":"Biomark Res"},{"key":"5266_CR182","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1158\/2159-8290.CD-21-1683","volume":"12","author":"RM Young","year":"2022","unstructured":"Young RM, Engel NW, Uslu U, Wellhausen N, June CH. Next-generation CAR T-cell therapies. Cancer Discov. 2022;12:1625\u201333.","journal-title":"Cancer Discov"},{"key":"5266_CR183","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1039\/D1LC00219H","volume":"21","author":"V Jayasooriya","year":"2021","unstructured":"Jayasooriya V, Ringwelski B, Dorsam G, Nawarathna D. mRNA-based CAR T-cells manufactured by miniaturized two-step electroporation produce selective cytotoxicity toward target cancer cells. Lab Chip. 2021;21:3748\u201361.","journal-title":"Lab Chip"},{"key":"5266_CR184","doi-asserted-by":"publisher","first-page":"101566","DOI":"10.1016\/j.beha.2024.101566","volume":"37","author":"S Chen","year":"2024","unstructured":"Chen S, van den Brink MR. Allogeneic Off-the-Shelf CAR T cells: Challenges and advances. Best Practice Research Clin Haematology. 2024;37:101566.","journal-title":"Best Practice Research Clin Haematology"},{"key":"5266_CR185","doi-asserted-by":"publisher","first-page":"1432799","DOI":"10.3389\/fimmu.2024.1432799","volume":"15","author":"A Ali","year":"2024","unstructured":"Ali A, DiPersio JF. ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights. Front Immunol. 2024;15:1432799.","journal-title":"Front Immunol"},{"key":"5266_CR186","doi-asserted-by":"crossref","unstructured":"Dias J, Garcia J, Agliardi G, Roddie C. CAR-T cell manufacturing landscape\u2014Lessons from the past decade and considerations for early clinical development. Mol Ther Methods Clin Dev.\u00a02024;32(2):101250.","DOI":"10.1016\/j.omtm.2024.101250"},{"key":"5266_CR187","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1172\/JCI39933","volume":"120","author":"KA Newell","year":"2010","unstructured":"Newell KA, et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Investig. 2010;120:1836\u201347.","journal-title":"J Clin Investig"},{"key":"5266_CR188","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/ajt.14185","volume":"17","author":"DA Boardman","year":"2017","unstructured":"Boardman DA, et al. Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection. Am J Transplant. 2017;17:931\u201343.","journal-title":"Am J Transplant"},{"key":"5266_CR189","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/ajt.14175","volume":"17","author":"F Noyan","year":"2017","unstructured":"Noyan F, et al. Prevention of allograft rejection by use of regulatory T cells with an MHC-specific chimeric antigen receptor. Am J Transplant. 2017;17:917\u201330.","journal-title":"Am J Transplant"},{"key":"5266_CR190","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-00462-8","volume":"7","author":"LJ Rupp","year":"2017","unstructured":"Rupp LJ, et al. CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep. 2017;7:1\u201310.","journal-title":"Sci Rep"},{"key":"5266_CR191","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/imm.13888","volume":"174","author":"S Zhu","year":"2025","unstructured":"Zhu S, Hu J, Lin J, Wang C, Wang E. Co-Expression of Dominant\u2010Negative TGF\u2010\u03b2 Receptor 2 Enhances the Therapeutic Efficacy of Novel TREM1\/DAP12\u2010BB\u2010Based CAR\u2010T Cells in Solid Tumours. Immunology. 2025;174:310\u201321.","journal-title":"Immunology"},{"key":"5266_CR192","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","volume":"71","author":"M Chmielewski","year":"2011","unstructured":"Chmielewski M, Kopecky C, Hombach AA, Abken H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 2011;71:5697\u2013706.","journal-title":"Cancer Res"},{"key":"5266_CR193","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1096\/fj.201901809R","volume":"34","author":"Y Huang","year":"2020","unstructured":"Huang Y, et al. IL-18R\u2010dependent and independent pathways account for IL\u201018\u2010enhanced antitumor ability of CAR\u2010T cells. FASEB J. 2020;34:1768\u201382.","journal-title":"FASEB J"},{"key":"5266_CR194","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/TP.0000000000001278","volume":"101","author":"RA Hornero","year":"2017","unstructured":"Hornero RA, et al. CD45RA distinguishes CD4\u2009+\u2009CD25+ CD127\u2013\/low TSDR demethylated regulatory T cell subpopulations with differential stability and susceptibility to tacrolimus-mediated inhibition of suppression. Transplantation. 2017;101:302\u20139.","journal-title":"Transplantation"},{"key":"5266_CR195","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1158\/1538-7445.AM2017-654","volume":"77","author":"D Sen","year":"2017","unstructured":"Sen D. The epigenetic landscape of T cell exhaustion. Cancer Res. 2017;77:654\u2013654.","journal-title":"Cancer Res"},{"key":"5266_CR196","doi-asserted-by":"publisher","first-page":"1688995","DOI":"10.3389\/fimmu.2025.1688995","volume":"16","author":"T Frlic","year":"2025","unstructured":"Frlic T, Pavlin M. Metabolic reprogramming of CAR T cells: a new frontier in cancer immunotherapy. Front Immunol. 2025;16:1688995.","journal-title":"Front Immunol"},{"key":"5266_CR197","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat reviews Clin Oncol. 2022;19:775\u201390.","journal-title":"Nat reviews Clin Oncol"},{"key":"5266_CR198","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1172\/JCI82771","volume":"126","author":"KG MacDonald","year":"2016","unstructured":"MacDonald KG, et al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J Clin Investig. 2016;126:1413\u201324.","journal-title":"J Clin Investig"},{"key":"5266_CR199","first-page":"1035","volume":"116","author":"B Jena","year":"2010","unstructured":"Jena B, Dotti G, Cooper LJ. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood J Am Soc Hematol. 2010;116:1035\u201344.","journal-title":"Blood J Am Soc Hematol"},{"key":"5266_CR200","doi-asserted-by":"publisher","first-page":"eaav1648","DOI":"10.1126\/scitranslmed.aav1648","volume":"11","author":"R Kansal","year":"2019","unstructured":"Kansal R, et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med. 2019;11:eaav1648.","journal-title":"Sci Transl Med"},{"key":"5266_CR201","doi-asserted-by":"publisher","unstructured":"Srivastava S, et al. Revolutionizing immunotherapy: unveiling new horizons, confronting challenges, and navigating therapeutic frontiers in CAR-T cell-based gene therapies. Immunotargets Ther. 2024;13:413\u201333. https:\/\/doi.org\/10.2147\/ITT.S474659.","DOI":"10.2147\/ITT.S474659"},{"key":"5266_CR202","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1097\/ICO.0000000000001720","volume":"37","author":"M Ito","year":"2018","unstructured":"Ito M, Iizuka-Koga M, Ando M, Yoshimura A. Development and functional modulation of regulatory T cells by transcription factors and epigenetics. Cornea. 2018;37:S42\u20139.","journal-title":"Cornea"},{"key":"5266_CR203","doi-asserted-by":"publisher","first-page":"1411393","DOI":"10.3389\/fimmu.2024.1411393","volume":"15","author":"M Rossi","year":"2024","unstructured":"Rossi M, Breman E. Engineering strategies to safely drive CAR T-cells into the future. Front Immunol. 2024;15:1411393.","journal-title":"Front Immunol"},{"key":"5266_CR204","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat reviews Clin Oncol. 2023;20:359\u201371.","journal-title":"Nat reviews Clin Oncol"},{"key":"5266_CR205","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21:581\u201390.","journal-title":"Nat Med"},{"key":"5266_CR206","doi-asserted-by":"publisher","first-page":"738456","DOI":"10.3389\/fimmu.2021.738456","volume":"12","author":"N Ghahri-Saremi","year":"2021","unstructured":"Ghahri-Saremi N, et al. Genetic modification of cytokine signaling to enhance efficacy of CAR T cell therapy in solid tumors. Front Immunol. 2021;12:738456.","journal-title":"Front Immunol"},{"key":"5266_CR207","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","volume":"3","author":"EW Weber","year":"2019","unstructured":"Weber EW, et al. Pharmacologic control of CAR-T cell function using dasatinib. Blood Adv. 2019;3:711\u20137.","journal-title":"Blood Adv"},{"key":"5266_CR208","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41590-024-02049-8","volume":"26","author":"F Song","year":"2025","unstructured":"Song F, Dotti G. A cocktail of kinase inhibitors that enhance the antitumor effects of CAR-T cell therapy. Nat Immunol. 2025;26:170\u20131.","journal-title":"Nat Immunol"},{"key":"5266_CR209","first-page":"372","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat reviews Clin Oncol. 2019;16:372\u201385.","journal-title":"Nat reviews Clin Oncol"},{"key":"5266_CR210","doi-asserted-by":"publisher","first-page":"106036","DOI":"10.1016\/j.phrs.2021.106036","volume":"175","author":"Z-Z Zhang","year":"2022","unstructured":"Zhang Z-Z, et al. Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies. Pharmacol Res. 2022;175:106036.","journal-title":"Pharmacol Res"},{"key":"5266_CR211","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat reviews Clin Oncol. 2020;17:147\u201367.","journal-title":"Nat reviews Clin Oncol"},{"key":"5266_CR212","doi-asserted-by":"publisher","first-page":"618387","DOI":"10.3389\/fimmu.2020.618387","volume":"11","author":"L Lindo","year":"2021","unstructured":"Lindo L, Wilkinson LH, Hay KA. Befriending the hostile tumor microenvironment in CAR T-cell therapy. Front Immunol. 2021;11:618387.","journal-title":"Front Immunol"},{"key":"5266_CR213","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","volume":"25","author":"LAK Fonkoua","year":"2022","unstructured":"Fonkoua LAK, Sirpilla O, Sakemura R, Siegler EL, Kenderian S. S. CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities. Mol Therapy-Oncolytics. 2022;25:69\u201377.","journal-title":"Mol Therapy-Oncolytics"},{"key":"5266_CR214","doi-asserted-by":"publisher","unstructured":"Zanvit P, van Dyk D, Fazenbaker C, McGlinchey K, Luo W, Pezold JM, Meekin J, Chang CY, Carrasco RA, Breen S, Cheung CSF. Antitumor activity of AZD0754, a dnTGF\u03b2RII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer. J Clin Invest. 2023;133(22):e169655. https:\/\/doi.org\/10.1172\/JCI169655.","DOI":"10.1172\/JCI169655"},{"key":"5266_CR215","doi-asserted-by":"publisher","first-page":"e008261","DOI":"10.1136\/jitc-2023-008261","volume":"12","author":"TM Tran","year":"2024","unstructured":"Tran TM, et al. Armored TGF\u03b2RIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGF\u03b21. J Immunother Cancer. 2024;12:e008261.","journal-title":"J Immunother Cancer"},{"key":"5266_CR216","doi-asserted-by":"publisher","first-page":"5413","DOI":"10.1158\/1078-0432.CCR-24-1853","volume":"30","author":"AM Barrett","year":"2024","unstructured":"Barrett AM, et al. Preclinical evaluation of AZD6422, an armored chimeric antigen receptor T cell targeting CLDN18. 2 in gastric, pancreatic, and esophageal cancers. Clin Cancer Res. 2024;30:5413\u201329.","journal-title":"Clin Cancer Res"},{"key":"5266_CR217","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/imr.12125","volume":"257","author":"M Chmielewski","year":"2014","unstructured":"Chmielewski M, Hombach AA, Abken H. Of CAR s and TRUCK s: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev. 2014;257:83\u201390.","journal-title":"Immunol Rev"},{"key":"5266_CR218","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","volume":"15","author":"M Chmielewski","year":"2015","unstructured":"Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther. 2015;15:1145\u201354.","journal-title":"Expert Opin Biol Ther"},{"key":"5266_CR219","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1016\/j.ymthe.2024.06.017","volume":"32","author":"L Ma","year":"2024","unstructured":"Ma L, et al. Building a novel TRUCK by harnessing the endogenous IFN-gamma promoter for cytokine expression. Mol Ther. 2024;32:2728\u201340.","journal-title":"Mol Ther"},{"key":"5266_CR220","doi-asserted-by":"publisher","first-page":"e005187","DOI":"10.1136\/jitc-2022-005187","volume":"10","author":"T Gargett","year":"2022","unstructured":"Gargett T, et al. GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma. J Immunother Cancer. 2022;10:e005187.","journal-title":"J Immunother Cancer"},{"key":"5266_CR221","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1158\/1078-0432.CCR-18-1811","volume":"25","author":"Y Chen","year":"2019","unstructured":"Chen Y, et al. Eradication of neuroblastoma by T cells redirected with an optimized GD2-specific chimeric antigen receptor and interleukin-15. Clin Cancer Res. 2019;25:2915\u201324.","journal-title":"Clin Cancer Res"},{"key":"5266_CR222","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","volume":"637","author":"D Steffin","year":"2025","unstructured":"Steffin D, et al. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. 2025;637:940\u20136.","journal-title":"Nature"},{"key":"5266_CR223","doi-asserted-by":"publisher","first-page":"e003633","DOI":"10.1136\/jitc-2021-003633","volume":"10","author":"J Hu","year":"2022","unstructured":"Hu J, et al. Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors. J Immunother Cancer. 2022;10:e003633.","journal-title":"J Immunother Cancer"},{"key":"5266_CR224","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","volume":"167","author":"KT Roybal","year":"2016","unstructured":"Roybal KT, et al. Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell. 2016;167:419\u201332.","journal-title":"Cell"},{"key":"5266_CR225","doi-asserted-by":"publisher","first-page":"eaba1624","DOI":"10.1126\/science.aba1624","volume":"378","author":"GM Allen","year":"2022","unstructured":"Allen GM, et al. Synthetic cytokine circuits that drive T cells into immune-excluded tumors. Science. 2022;378:eaba1624.","journal-title":"Science"},{"key":"5266_CR226","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/resp.14541","volume":"28","author":"G Li","year":"2023","unstructured":"Li G, et al. Overexpression of SMAD7 improves the function of EGFR-targeted human CAR\u2010T cells against non\u2010small\u2010cell lung cancer. Respirology. 2023;28:869\u201380.","journal-title":"Respirology"},{"key":"5266_CR227","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41423-023-01120-y","volume":"21","author":"S Liang","year":"2024","unstructured":"Liang S, et al. SMAD7 expression in CAR-T cells improves persistence and safety for solid tumors. Cellular Molecular Immunology. 2024;21:213\u201326.","journal-title":"Cellular Molecular Immunology"},{"key":"5266_CR228","doi-asserted-by":"publisher","first-page":"1164535","DOI":"10.3389\/fonc.2023.1164535","volume":"13","author":"M Proietto","year":"2023","unstructured":"Proietto M, et al. Tumor heterogeneity: preclinical models, emerging technologies, and future applications. Front Oncol. 2023;13:1164535.","journal-title":"Front Oncol"},{"key":"5266_CR229","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s12916-023-03016-0","volume":"21","author":"C Yang","year":"2023","unstructured":"Yang C, et al. Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma. BMC Med. 2023;21:327.","journal-title":"BMC Med"},{"key":"5266_CR230","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cancergen.2022.10.003","volume":"268","author":"Y Wang","year":"2022","unstructured":"Wang Y, et al. Mesothelin CAR-T cells secreting PD\u2010L1 blocking scFv for pancreatic cancer treatment. Cancer Genet. 2022;268:103\u201310.","journal-title":"Cancer Genet"},{"key":"5266_CR231","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/s41579-024-01010-8","volume":"22","author":"M Armani-Tourret","year":"2024","unstructured":"Armani-Tourret M, et al. Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure. Nat Rev Microbiol. 2024;22:328\u201344.","journal-title":"Nat Rev Microbiol"},{"key":"5266_CR232","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1172\/JCI80566","volume":"126","author":"RB Jones","year":"2016","unstructured":"Jones RB, Walker BD. HIV-specific CD8\u2009+\u2009T cells and HIV eradication. J Clin Investig. 2016;126:455\u201363.","journal-title":"J Clin Investig"},{"key":"5266_CR233","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/MOP.0000000000000304","volume":"28","author":"K Rainwater-Lovett","year":"2016","unstructured":"Rainwater-Lovett K, Uprety P, Persaud D. Advances and hope for perinatal HIV remission and cure in children and adolescents. Curr Opin Pediatr. 2016;28:86\u201392.","journal-title":"Curr Opin Pediatr"},{"key":"5266_CR234","doi-asserted-by":"publisher","first-page":"e1003211","DOI":"10.1371\/journal.ppat.1003211","volume":"9","author":"A S\u00e1ez-Ciri\u00f3n","year":"2013","unstructured":"S\u00e1ez-Ciri\u00f3n A, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 2013;9:e1003211.","journal-title":"PLoS Pathog"},{"key":"5266_CR235","doi-asserted-by":"publisher","first-page":"ra13253","DOI":"10.1126\/scitranslmed.3003761","volume":"4","author":"J Scholler","year":"2012","unstructured":"Scholler J, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med. 2012;4:ra13253\u201313253.","journal-title":"Sci Transl Med"},{"key":"5266_CR236","first-page":"467","volume":"96","author":"RE Walker","year":"2000","unstructured":"Walker RE, et al. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood J Am Soc Hematol. 2000;96:467\u201374.","journal-title":"Blood J Am Soc Hematol"},{"key":"5266_CR237","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nrc.2016.97","volume":"16","author":"AD Fesnak","year":"2016","unstructured":"Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. 2016;16:566\u201381.","journal-title":"Nat Rev Cancer"},{"key":"5266_CR238","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.celrep.2017.09.015","volume":"21","author":"D Gomes-Silva","year":"2017","unstructured":"Gomes-Silva D, et al. Tonic 4-1BB costimulation in chimeric antigen receptors impedes T cell survival and is vector-dependent. Cell Rep. 2017;21:17\u201326.","journal-title":"Cell Rep"},{"key":"5266_CR239","doi-asserted-by":"publisher","first-page":"e1006613","DOI":"10.1371\/journal.ppat.1006613","volume":"13","author":"RS Leibman","year":"2017","unstructured":"Leibman RS, et al. Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor. PLoS Pathog. 2017;13:e1006613.","journal-title":"PLoS Pathog"},{"key":"5266_CR240","doi-asserted-by":"publisher","first-page":"9712","DOI":"10.1128\/JVI.00852-16","volume":"90","author":"B Liu","year":"2016","unstructured":"Liu B, et al. Chimeric antigen receptor T cells guided by the single-chain Fv of a broadly neutralizing antibody specifically and effectively eradicate virus reactivated from latency in CD4\u2009+\u2009T lymphocytes isolated from HIV-1-infected individuals receiving suppressive combined antiretroviral therapy. J Virol. 2016;90:9712\u201324.","journal-title":"J Virol"},{"key":"5266_CR241","doi-asserted-by":"publisher","first-page":"6685","DOI":"10.1128\/JVI.00474-15","volume":"89","author":"L Liu","year":"2015","unstructured":"Liu L, et al. Novel CD4-based bispecific chimeric antigen receptor designed for enhanced anti-HIV potency and absence of HIV entry receptor activity. J Virol. 2015;89:6685\u201394.","journal-title":"J Virol"},{"key":"5266_CR242","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jcyt.2017.11.001","volume":"20","author":"MH Ghanem","year":"2018","unstructured":"Ghanem MH, et al. Bispecific chimeric antigen receptors targeting the CD4 binding site and high-mannose Glycans of gp120 optimized for anti\u2013human immunodeficiency virus potency and breadth with minimal immunogenicity. Cytotherapy. 2018;20:407\u201319.","journal-title":"Cytotherapy"},{"key":"5266_CR243","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1182\/blood.V120.21.3014.3014","volume":"120","author":"X Wang","year":"2012","unstructured":"Wang X, et al. Enhanced Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV Specific Central Memory T Cells by CMV Vaccine. Blood. 2012;120:3014.","journal-title":"Blood"},{"key":"5266_CR244","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40425-015-0049-1","volume":"3","author":"J Sun","year":"2015","unstructured":"Sun J, et al. Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a production assistant for cell therapy (PACT) translational application. J Immunother Cancer. 2015;3:5.","journal-title":"J Immunother Cancer"},{"key":"5266_CR245","unstructured":"National Institutes of Health. US National Library of Medicine. ClinicalTrials. gov. Clinical study to investigate the effect of the combination of psychotropic drugs and an opioid on ventilation. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04310579. Accessed May 15, (2020)."},{"key":"5266_CR246","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1158\/2326-6066.CIR-14-0186","volume":"3","author":"MJ Frigault","year":"2015","unstructured":"Frigault MJ, et al. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol Res. 2015;3:356\u201367.","journal-title":"Cancer Immunol Res"},{"key":"5266_CR247","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/nm.3647","volume":"20","author":"A Mendelson","year":"2014","unstructured":"Mendelson A, Frenette PS. Hematopoietic stem cell niche maintenance during homeostasis and regeneration. Nat Med. 2014;20:833\u201346.","journal-title":"Nat Med"},{"key":"5266_CR248","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/v6010001","volume":"6","author":"A Zhen","year":"2013","unstructured":"Zhen A, Kitchen S. Stem-cell-based gene therapy for HIV infection. Viruses. 2013;6:1\u201312.","journal-title":"Viruses"},{"key":"5266_CR249","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1038\/mt.2015.102","volume":"23","author":"A Zhen","year":"2015","unstructured":"Zhen A, et al. HIV-specific immunity derived from chimeric antigen receptor-engineered stem cells. Mol Ther. 2015;23:1358\u201367.","journal-title":"Mol Ther"},{"key":"5266_CR250","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1182\/bloodadvances.2017012971","volume":"2","author":"GM Webb","year":"2018","unstructured":"Webb GM, et al. The human IL-15 superagonist ALT-803 directs SIV-specific CD8\u2009+\u2009T cells into B-cell follicles. Blood Adv. 2018;2:76\u201384.","journal-title":"Blood Adv"},{"key":"5266_CR251","doi-asserted-by":"publisher","first-page":"e1005545","DOI":"10.1371\/journal.ppat.1005545","volume":"12","author":"RB Jones","year":"2016","unstructured":"Jones RB, et al. A subset of latency-reversing agents expose HIV-infected resting CD4\u2009+\u2009T-cells to recognition by cytotoxic T-lymphocytes. PLoS Pathog. 2016;12:e1005545.","journal-title":"PLoS Pathog"},{"key":"5266_CR252","doi-asserted-by":"publisher","first-page":"e20191663","DOI":"10.1084\/jem.20191663","volume":"217","author":"A Bertoletti","year":"2020","unstructured":"Bertoletti A, Tan AT. Challenges of CAR-and TCR-T cell\u2013based therapy for chronic infections. J Exp Med. 2020;217:e20191663.","journal-title":"J Exp Med"},{"key":"5266_CR253","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1084\/jem.191.8.1263","volume":"191","author":"B Rehermann","year":"2000","unstructured":"Rehermann B. Intrahepatic T cells in hepatitis B: viral control versus liver cell injury. J Exp Med. 2000;191:1263\u20138.","journal-title":"J Exp Med"},{"key":"5266_CR254","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh L, Mackall CL. CAR immune cells: design principles, resistance and the next generation. Nature. 2023;614:635\u201348.","journal-title":"Nature"},{"key":"5266_CR255","doi-asserted-by":"publisher","first-page":"e2320053121","DOI":"10.1073\/pnas.2320053121","volume":"121","author":"JL Yang","year":"2024","unstructured":"Yang JL, et al. Directed evolution of genetically encoded LYTACs for cell-mediated delivery. Proc Natl Acad Sci. 2024;121:e2320053121.","journal-title":"Proc Natl Acad Sci"},{"key":"5266_CR256","unstructured":"Abbas AK, Lichtman AH, Pillai S. Basic immunology E-book: basic immunology E-Book. Elsevier Health Sciences; 2023."},{"key":"5266_CR257","doi-asserted-by":"crossref","unstructured":"Stein DN, Gendelman HE. CAR Treg therapies for neurodegenerative diseases. iScience. 2026;29.","DOI":"10.1016\/j.isci.2026.114988"},{"key":"5266_CR258","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.humimm.2017.10.007","volume":"79","author":"J Levitsky","year":"2018","unstructured":"Levitsky J, Feng S. Tolerance in clinical liver transplantation. Hum Immunol. 2018;79:283\u20137.","journal-title":"Hum Immunol"},{"key":"5266_CR259","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1172\/JCI39922","volume":"120","author":"P Sagoo","year":"2010","unstructured":"Sagoo P, et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Investig. 2010;120:1848\u201361.","journal-title":"J Clin Investig"},{"key":"5266_CR260","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1111\/ajt.16395","volume":"21","author":"PN Harden","year":"2021","unstructured":"Harden PN, et al. Feasibility, long-term safety, and immune monitoring of regulatory T cell therapy in living donor kidney transplant recipients. Am J Transplant. 2021;21:1603\u201311.","journal-title":"Am J Transplant"},{"key":"5266_CR261","doi-asserted-by":"crossref","unstructured":"Roemhild A, et al. Regulatory T cells for minimising immune suppression in kidney transplantation: phase I\/IIa clinical trial. BMJ. 2020;371.","DOI":"10.1136\/bmj.m3734"},{"key":"5266_CR262","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1111\/ajt.14415","volume":"17","author":"S Chandran","year":"2017","unstructured":"Chandran S, et al. Polyclonal regulatory T cell therapy for control of inflammation in kidney transplants. Am J Transplant. 2017;17:2945\u201354.","journal-title":"Am J Transplant"},{"key":"5266_CR263","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nm1688","volume":"14","author":"O Joffre","year":"2008","unstructured":"Joffre O, et al. Prevention of acute and chronic allograft rejection with CD4\u2009+\u2009CD25+ Foxp3\u2009+\u2009regulatory T lymphocytes. Nat Med. 2008;14:88\u201392.","journal-title":"Nat Med"},{"key":"5266_CR264","doi-asserted-by":"publisher","first-page":"ra8342","DOI":"10.1126\/scitranslmed.3002076","volume":"3","author":"P Sagoo","year":"2011","unstructured":"Sagoo P, et al. Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci Transl Med. 2011;3:ra8342\u20138342.","journal-title":"Sci Transl Med"},{"key":"5266_CR265","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1084\/jem.181.5.1653","volume":"181","author":"T Brocker","year":"1995","unstructured":"Brocker T, Karjalainen K. Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J Exp Med. 1995;181:1653\u20139.","journal-title":"J Exp Med"},{"key":"5266_CR266","doi-asserted-by":"publisher","first-page":"eaaz3866","DOI":"10.1126\/scitranslmed.aaz3866","volume":"12","author":"NA Dawson","year":"2020","unstructured":"Dawson NA, et al. Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T cells. Sci Transl Med. 2020;12:eaaz3866.","journal-title":"Sci Transl Med"},{"key":"5266_CR267","doi-asserted-by":"publisher","first-page":"e136185","DOI":"10.1172\/jci.insight.136185","volume":"5","author":"Y Imura","year":"2020","unstructured":"Imura Y, Ando M, Kondo T, Ito M, Yoshimura A. CD19-targeted CAR regulatory T cells suppress B cell pathology without GvHD. Jci Insight. 2020;5:e136185.","journal-title":"Jci Insight"},{"key":"5266_CR268","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/iji.12000","volume":"40","author":"C Burt","year":"2013","unstructured":"Burt C, Cryer C, Fuggle S, Little A, Dyer P. HLA-A,\u2010B,\u2010DR allele group frequencies in 7007 kidney transplant list patients in 27 UK centres. Int J Immunogenet. 2013;40:209\u201315.","journal-title":"Int J Immunogenet"},{"key":"5266_CR269","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1111\/ajt.15787","volume":"20","author":"A Sicard","year":"2020","unstructured":"Sicard A, et al. Donor-specific chimeric antigen receptor Tregs limit rejection in naive but not sensitized allograft recipients. Am J Transplant. 2020;20:1562\u201373.","journal-title":"Am J Transplant"},{"key":"5266_CR270","doi-asserted-by":"publisher","first-page":"e123672","DOI":"10.1172\/jci.insight.123672","volume":"4","author":"NA Dawson","year":"2019","unstructured":"Dawson NA, et al. Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in regulatory T cells. JCI insight. 2019;4:e123672.","journal-title":"JCI insight"},{"key":"5266_CR271","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1034\/j.1399-0039.2000.550305.x","volume":"55","author":"N Watkins","year":"2000","unstructured":"Watkins N, Brown C, Hurd C, Navarrete C, Ouwehand W. The isolation and characterisation of human monoclonal HLA-A2 antibodies from an immune V gene phage display library. Tissue Antigens. 2000;55:219\u201328.","journal-title":"Tissue Antigens"},{"key":"5266_CR272","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S0198-8859(97)00146-8","volume":"56","author":"A Mulder","year":"1997","unstructured":"Mulder A, Kardol M, Regan J, Buelow R, Claas F. Reactivity of Twenty-two Cytotoxic Human Monoclonal HLA Antibodies Towards Soluble HLA Class I in an Enzyme-Linked Immunosorbent Assay (PRA-STAT\u00ae). Hum Immunol. 1997;56:106\u201313.","journal-title":"Hum Immunol"},{"key":"5266_CR273","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/j.ard.2025.06.1816","volume":"84","author":"A Ugolini","year":"2025","unstructured":"Ugolini A, et al. ABS0179 UNDERSTANDING CAR-TREG PERSISTENCE AND EXPANSION PROTOCOLS OPTIMIZATION. Ann Rheum Dis. 2025;84:2181\u20132.","journal-title":"Ann Rheum Dis"},{"key":"5266_CR274","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/08830185.2023.2274574","volume":"43","author":"R Zhang","year":"2024","unstructured":"Zhang R, et al. Low-dose IL-2 therapy in autoimmune diseases: An update review. Int Rev Immunol. 2024;43:113\u201337.","journal-title":"Int Rev Immunol"},{"key":"5266_CR275","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/cei\/uxac105","volume":"211","author":"F Harris","year":"2023","unstructured":"Harris F, Berdugo YA, Tree T. IL-2-based approaches to Treg enhancement. Clin Exp Immunol. 2023;211:149\u201363.","journal-title":"Clin Exp Immunol"},{"key":"5266_CR276","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood cancer J. 2021;11:69.","journal-title":"Blood cancer J"},{"key":"5266_CR277","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.jaci.2018.07.014","volume":"142","author":"C Schmidl","year":"2018","unstructured":"Schmidl C, Delacher M, Huehn J, Feuerer M. Epigenetic mechanisms regulating T-cell responses. J Allergy Clin Immunol. 2018;142:728\u201343.","journal-title":"J Allergy Clin Immunol"},{"key":"5266_CR278","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.tibtech.2019.12.009","volume":"38","author":"E Fritsche","year":"2020","unstructured":"Fritsche E, Volk H-D, Reinke P. Abou-El-Enein, M. Toward an optimized process for clinical manufacturing of CAR-Treg cell therapy. Trends Biotechnol. 2020;38:1099\u2013112.","journal-title":"Trends Biotechnol"},{"key":"5266_CR279","first-page":"1277","volume":"124","author":"B Philip","year":"2014","unstructured":"Philip B, et al. A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy. Blood J Am Soc Hematol. 2014;124:1277\u201387.","journal-title":"Blood J Am Soc Hematol"},{"key":"5266_CR280","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1172\/JCI84813","volume":"126","author":"PJ Paszkiewicz","year":"2016","unstructured":"Paszkiewicz PJ, et al. Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. J Clin Investig. 2016;126:4262\u201372.","journal-title":"J Clin Investig"},{"key":"5266_CR281","first-page":"4103","volume":"125","author":"X Zhou","year":"2015","unstructured":"Zhou X, et al. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood J Am Soc Hematol. 2015;125:4103\u201313.","journal-title":"Blood J Am Soc Hematol"},{"key":"5266_CR282","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28:2124\u201332.","journal-title":"Nat Med"},{"key":"5266_CR283","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","volume":"20","author":"G Schett","year":"2024","unstructured":"Schett G, et al. Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nat Rev Rheumatol. 2024;20:531\u201344.","journal-title":"Nat Rev Rheumatol"},{"key":"5266_CR284","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1182\/blood.V128.22.218.218","volume":"128","author":"III Lee","year":"2016","unstructured":"Lee III. Long-term outcomes following CD19 CAR T cell therapy for B-ALL are superior in patients receiving a fludarabine\/cyclophosphamide preparative regimen and post-CAR hematopoietic stem cell transplantation. Blood. 2016;128:218.","journal-title":"Blood"},{"key":"5266_CR285","doi-asserted-by":"publisher","first-page":"77","DOI":"10.4049\/jimmunol.204.Supp.77.16","volume":"204","author":"J-C Beltra","year":"2020","unstructured":"Beltra J-C, et al. Developmental relationships of four exhausted CD8 T cell subsets reveals underlying transcriptional and epigenetic control mechanisms. J Immunol. 2020;204:77\u201316.","journal-title":"J Immunol"},{"key":"5266_CR286","doi-asserted-by":"publisher","first-page":"923","DOI":"10.20892\/j.issn.2095-3941.2020.0338","volume":"17","author":"Z Zeng","year":"2020","unstructured":"Zeng Z, Wei F, Ren X. Exhausted T cells and epigenetic status. Cancer biology medicine. 2020;17:923\u201336.","journal-title":"Cancer biology medicine"},{"key":"5266_CR287","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.immuni.2009.03.019","volume":"30","author":"M Miyara","year":"2009","unstructured":"Miyara M, et al. Functional delineation and differentiation dynamics of human CD4\u2009+\u2009T cells expressing the FoxP3 transcription factor. Immunity. 2009;30:899\u2013911.","journal-title":"Immunity"},{"key":"5266_CR288","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1111\/ajt.15306","volume":"19","author":"K Ratnasothy","year":"2019","unstructured":"Ratnasothy K, et al. IL-2 therapy preferentially expands adoptively transferred donor-specific Tregs improving skin allograft survival. Am J Transplant. 2019;19:2092\u2013100.","journal-title":"Am J Transplant"},{"key":"5266_CR289","doi-asserted-by":"publisher","first-page":"7083","DOI":"10.1073\/pnas.1620835114","volume":"114","author":"G Whitehouse","year":"2017","unstructured":"Whitehouse G, et al. IL-2 therapy restores regulatory T-cell dysfunction induced by calcineurin inhibitors. Proc Natl Acad Sci. 2017;114:7083\u20138.","journal-title":"Proc Natl Acad Sci"},{"key":"5266_CR290","first-page":"1255","volume":"118","author":"X Wang","year":"2011","unstructured":"Wang X, et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood J Am Soc Hematol. 2011;118:1255\u201363.","journal-title":"Blood J Am Soc Hematol"},{"key":"5266_CR291","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.humimm.2021.12.002","volume":"83","author":"S Bezstarosti","year":"2022","unstructured":"Bezstarosti S, et al. Implementation of molecular matching in transplantation requires further characterization of both immunogenicity and antigenicity of individual HLA epitopes. Hum Immunol. 2022;83:256\u201363.","journal-title":"Hum Immunol"},{"key":"5266_CR292","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp S, Mufti G, Poirot L. Off-the-shelf\u2019allogeneic CAR T cells: development and challenges. Nat Rev Drug Discovery. 2020;19:185\u201399.","journal-title":"Nat Rev Drug Discovery"},{"key":"5266_CR293","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","volume":"168","author":"WA Lim","year":"2017","unstructured":"Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell. 2017;168:724\u201340.","journal-title":"Cell"},{"key":"5266_CR294","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361\u20135.","journal-title":"Science"},{"key":"5266_CR295","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"RC Larson","year":"2021","unstructured":"Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21:145\u201361.","journal-title":"Nat Rev Cancer"},{"key":"5266_CR296","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377:2545\u201354.","journal-title":"N Engl J Med"},{"key":"5266_CR297","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1016\/j.apsb.2024.04.022","volume":"14","author":"D Xiong","year":"2024","unstructured":"Xiong D, Yu H, Sun Z-J. Unlocking T cell exhaustion: Insights and implications for CAR-T cell therapy. Acta Pharm Sinica B. 2024;14:3416\u201331.","journal-title":"Acta Pharm Sinica B"},{"key":"5266_CR298","doi-asserted-by":"publisher","first-page":"9669","DOI":"10.3390\/ijms26199669","volume":"26","author":"Y Lin","year":"2025","unstructured":"Lin Y, et al. Limitations of CAR-T-Cell Therapy in Hematologic Malignancies: Focusing on Antigen Escape and T-Cell Dysfunction. Int J Mol Sci. 2025;26:9669.","journal-title":"Int J Mol Sci"},{"key":"5266_CR299","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","volume":"164","author":"KT Roybal","year":"2016","unstructured":"Roybal KT, et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell. 2016;164:770\u20139.","journal-title":"Cell"},{"key":"5266_CR300","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-019-0763-0","volume":"12","author":"D Liu","year":"2019","unstructured":"Liu D, Zhao J, Song Y. Engineering switchable and programmable universal CARs for CAR T therapy. Journal Hematology Oncology. 2019;12:69.","journal-title":"Journal Hematology Oncology"},{"key":"5266_CR301","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","volume":"567","author":"J Chen","year":"2019","unstructured":"Chen J, L\u00f3pez-Moyado IF, Seo H, Lio CWJ, Hempleman LJ, Sekiya T, Yoshimura A, Scott-Browne JP, Rao A. NR4A transcription factors limit CAR T cell function in solid tumours. Nature. 2019;567(7749):530\u201334.","journal-title":"Nature"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-026-05266-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-05266-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-05266-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:02:31Z","timestamp":1788912151000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13287-026-05266-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,6]]},"references-count":301,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5266"],"URL":"https:\/\/doi.org\/10.1186\/s13287-026-05266-0","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,6]]},"assertion":[{"value":"11 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"309"}}